Comparison of Long-acting Buprenorphine (Sublocade) and Naltrexone Opioid Treatments Among Justice-involved Individuals Leaving Jails (035)

Active

Study Information

The New York University (NYU) School of Medicine JCOIN Research Center conducting a large multisite trial to compare the effectiveness of extended-release buprenorphine (Sublocade, XR-B) to extended-release naltrexone (XR-NTX). The trial will enroll individuals prior to release from jail and randomize to either medication option. The first dose of medication will be administered prior to release, with an additional 24 weeks of treatment received in the community.

Participating jails are located in Connecticut, Delaware, New Hampshire, New Jersey, and Oregon. The study will measure retention in treatment, and opioid and other substance use outcomes between the two medication conditions, as well as a sample of individuals who opt for other treatment options (“treatment as usual”).


Study Settings: Jails/Prisons, Treatment/Healthcare Settings

Study Locations: Connecticut, Delaware, New Hampshire, New Jersey, Oregon

Study Team

PI/MPI:

Joshua Lee, MD, MSc
New York University School of Medicine

David Farabee, PhD
New York University School of Medicine

Lisa Marsch, MD
Dartmouth College

Robert Schwartz, MD
Friends Research Institute

Sandra Springer, MD
Yale School of Medicine

Elizabeth Waddell, MD
Oregon Health & Science University


Health Agency Partner:

Kasey Harding
Community Health Center, Inc.


Justice Agency Partner:

Thomas Groblewski, DO
New Hampshire Department of Corrections

NYU School of Medicine Logo

Study Aims

• Compare the effectiveness of XR-B vs XR-NTX on medication adherence (retention)

• Measure opioid and other substance use outcomes

• Compare study subjects to a treatment-as-usual sample

• Identify implications for the use of long-acting injectable MOUD in justice settings

Research Type

Clinical Trial, MOUD Comparative Effectiveness